ACADIA PHARMACEUTICALS INCACAD
Market cap
$3.9B
P/E ratio
| Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | |
| Total revenues | - | - | - | - | - | - | - | 224 | 339 | 442 | 484 | 517 | 726 | 958 |
| Cost of product sales | - | - | - | - | - | - | - | - | 11 | 10 | 11 | 10 | 42 | 82 |
| Research and development | 17 | 19 | 27 | 61 | 74 | 99 | 149 | 187 | 240 | 319 | 239 | 362 | 352 | 303 |
| Selling, general and administrative | - | - | - | - | - | 186 | 255 | 266 | 326 | 389 | 396 | 369 | 407 | 488 |
| Gain on sale of non-financial asset | - | - | - | - | - | - | - | - | - | - | - | - | - | 147 |
| Total operating expenses | - | - | - | - | - | 290 | 417 | 471 | 586 | 728 | 655 | 741 | 800 | 727 |
| Income (loss) from operations | -23 | -21 | -38 | -93 | -165 | -273 | -292 | -247 | -247 | -287 | -170 | -224 | -73 | 231 |
| Interest income, net | - | - | 0 | 1 | 0 | 3 | 4 | 5 | 11 | 7 | 1 | 7 | 17 | 25 |
| Other income | - | - | - | - | - | - | - | - | 1 | -1 | -2 | 4 | 5 | 2 |
| Income (loss) before income taxes | - | - | - | - | -164 | -270 | -288 | -244 | -234 | -281 | -168 | -213 | -51 | 258 |
| Income tax expense | - | - | - | - | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 3 | 10 | 32 |
| Net income (loss) | -23 | -21 | -38 | -92 | -164 | -271 | -289 | -245 | -235 | -282 | -168 | -216 | -61 | 226 |
| Earnings Per Share, Basic | -0.44 | -0.38 | - | - | - | - | - | - | - | - | - | -1.34 | -0.37 | 1.37 |
| Earnings Per Share, Diluted | -0.44 | -0.38 | - | - | - | - | - | - | - | - | - | -1.34 | -0.37 | 1.36 |